Promyelocytic leukemia protein modulates establishment and maintenance of latent gammaherpesvirus infection in peritoneal cells

Journal of Virology

Volumn 87, Issue 22, 2013, Pages 12151-12157

  Sewatanon, Jaturong ^a,b   Liu, Hao ^a   Ling, Paul D ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN; MESSENGER RNA; NUCLEAR PROTEIN; PML PROTEIN, MOUSE; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; EMBRYO; GAMMAHERPESVIRINAE; HERPES VIRUS INFECTION; IN VIVO STUDY; LATENT VIRUS INFECTION; LUNG; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PERITONEUM CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; SPLEEN; SPLENOMEGALY; VIRUS GENOME; VIRUS REACTIVATION; VIRUS REPLICATION; WILD TYPE; ANIMAL; ANIMAL EMBRYO; FIBROBLAST; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOGENICITY; PATHOLOGY; PERITONEUM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY; VIRUS LATENCY; WESTERN BLOTTING;

HERPESVIRIDAE; MURINAE; MUS;

ANIMALS; BLOTTING, WESTERN; EMBRYO, MAMMALIAN; FIBROBLASTS; FLOW CYTOMETRY; GAMMAHERPESVIRINAE; GENE EXPRESSION REGULATION, VIRAL; GENOME, VIRAL; HERPESVIRIDAE INFECTIONS; MICE; MICE, KNOCKOUT; NUCLEAR PROTEINS; PERITONEUM; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84886256811     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01696-13     Document Type: Article

References (50)

1. Pellett PE, Roizman B. 2007. The family Herpesviridae: a brief introduction, p 2479-2499. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams&Wilkins, Philadelphia, PA.
2. Speck SH, Ganem D. 2010. Viral latency and its regulation: lessons from the gamma-herpesviruses. Cell Host Microbe 8:100-115.
3. Virgin HW, Wherry EJ, Ahmed R. 2009. Redefining chronic viral infection. Cell 138:30-50.
4. Jung JU, Speck SH. 2013. Insights into chronic gamma-herpesvirus infections. Curr. Opin. Virol. 3:225-226.
5. Tibbetts SA, van Dyk LF, Speck SH, Virgin HW. 2002. Immune control of the number and reactivation phenotype of cells latently infected with a gammaherpesvirus. J. Virol. 76:7125-7132.
6. Lallemand-Breitenbach V, de Thé H. 2010. PML nuclear bodies. Cold Spring Harbor Perspect. Biol. 2:a000661.
7. Negorev D, Maul GG. 2001. Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 20:7234-7242.
8. Heuser M, van der Kuip H, Falini B, Peschel C, Huber C, Fischer T. 1998. Induction of the pro-myelocytic leukaemia gene by type I and type II interferons. Mediators Inflamm. 7:319-325.
9. Ling PD, Tan J, Sewatanon J, Peng R. 2008. Murine gammaherpesvirus 68 open reading frame 75c tegument protein induces the degradation of PML and is essential for production of infectious virus. J. Virol. 82:8000-8012.
10. Bonilla WV, Pinschewer DD, Klenerman P, Rousson V, Gaboli M, PandolfiPP, Zinkernagel RM, Salvato MS, Hengartner H. 2002. Effects of promyelocytic leukemia protein on virus-host balance. J. Virol. 76: 3810-3818.
11. Chee AV, Lopez P, PandolfiPP, Roizman B. 2003. Promyelocytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects. J. Virol. 77:7101-7105.
12. Everett RD, Chelbi-Alix MK. 2007. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89:819-830.
13. Everett RD, Freemont P, Saitoh H, Dasso M, Orr A, Kathoria M, Parkinson J. 1998. The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110 and proteasome-dependent loss of several PML isoforms. J. Virol. 72:6581-6591.
14. Wang L, Oliver SL, Sommer M, Rajamani J, Reichelt M, Arvin AM. 2011. Disruption of PML nuclear bodies is mediated by ORF61 SUMOinteracting motifs and required for varicella-zoster virus pathogenesis in skin. PLoS Pathog. 7:e1002157.
15. Ahn JH, Hayward GS. 1997. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PMLassociated nuclear bodies at very early times in infected permissive cells. J. Virol. 71:4599-4613.
16. Sivachandran N, Sarkari F, Frappier L. 2008. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies. PLoS Pathog. 4:e1000170.
17. Ling PD, Peng RS, Nakajima A, Yu JH, Tan J, Moses SM, Yang W-H, Zhao B, KieffE, Bloch KD, Bloch DB. 2005. Mediation of Epstein-Barr virus EBNA-LP transcriptional coactivation by Sp100. EMBO J. 24:3565-3575.
18. Adamson AL, Kenney S. 2001. Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J. Virol. 75:2388-2399.
19. Marcos-Villar L, Lopitz-Otsoa F, Gallego P, Muñoz-Fontela C, González-Santamaría J, Campagna M, Shou-Jiang G, Rodriguez MS, Rivas C. 2009. Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. J. Virol. 83:8849-8858.
20. Everett RD, Rechter S, Papior P, Tavalai N, Stamminger T, Orr A. 2006. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J. Virol. 80:7995-8005.
21. Wang S, Long J, Zheng C-F. 2012. The potential link between PML NBs and ICP0 in regulating lytic and latent infection of HSV-1. Protein Cell 3:372-382.
22. Tavalai N, Papior P, Rechter S, Leis M, Stamminger T. 2006. Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections. J. Virol. 80:8006-8018.
23. Halford WP, Weisend C, Grace J, Soboleski M, Carr DJJ, Balliet JW, Imai Y, Margolis TP, Gebhardt BM. 2006. ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency. Virol. J. 3:44. doi:10.1186/1743-422X-3-44.
24. Simas JP, Efstathiou S. 1998. Murine gammaherpesvirus 68: a model for the study of gammaherpesvirus pathogenesis. Trends Microbiol. 6:276-282.
25. Nash AA, Dutia BM, Stewart JP, Davison AJ. 2001. Natural history of murine gamma-herpesvirus infection. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:569-579.
26. Sewatanon J, Ling PD. 2013. Murine gammaherpesvirus 68 ORF75c contains ubiquitin E3 ligase activity and requires PML SUMOylation but not other known cellularPMLregulators, CK2 and E6AP, to mediatePML degradation. Virology 440:140-149.
27. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C, Grosveld F, PandolfiPP. 1998. Role of PML in cell growth and the retinoic acid pathway. Science 279:1547-1551.
28. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, PandolfiPP. 1998. PML is essential for multiple apoptotic pathways. Nat. Genet. 20:266-272.
29. Weck KE, Barkon ML, Yoo LI, Speck SH, Virgin HW, IV. 1996. Mature B cells are required for acute splenic infection, but not for establishment of latency, by murine gammaherpesvirus 68. J. Virol. 70:6775-6780.
30. Weck KE, Kim SS, Virgin HW, IV, Speck SH. 1999. B cells regulate murine gammaherpesvirus 68 latency. J. Virol. 73:4651-4661.
31. Weck KE, Kim SS, Virgin HW, IV, Speck SH. 1999. Macrophages are the major reservoir of latent murine gammaherpesvirus 68 in peritoneal cells. J. Virol. 73:3273-3283.
32. Efstathiou S, Ho YM, Minson AC. 1990. Cloning and molecular characterization of the murine herpesvirus 68 genome. J. Gen. Virol. 71:1355-1364.
33. Bonnefoix T, Bonnefoix P, Callanan M, Verdiel P, Sotto JJ. 2001. Graphical representation of a generalized linear model-based statistical test estimating the fit of the single-hit Poisson model to limiting dilution assays. J. Immunol. 167:5725-5730.
34. Condit RC. 2007. Principles of virology, p 39-40. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams&Wilkins, Philadelphia, PA.
35. Sunil-Chandra NP, Efstathiou S, Arno J, Nash AA. 1992. Virological and pathological features of mice infected with murine gamma-herpesvirus 68. J. Gen. Virol. 73:2347-2356.
36. Usherwood EJ, Ross AJ, Allen DJ, Nash AA. 1996. Murine gammaherpesvirus-induced splenomegaly: a critical role for CD4 T cells. J. Gen. Virol. 77:627-630.
37. Sarawar SR, Cardin RD, Brooks JW, Mehrpooya M, Tripp RA, Doherty PC. 1996. Cytokine production in the immune response to murine gammaherpesvirus 68. J. Virol. 70:3264-3268.
38. Tibbetts SA, Loh J, Van Berkel V, McClellan JS, Jacoby MA, Kapadia SB, Speck SH, Virgin HW. 2003. Establishment and maintenance of gammaherpesvirus latency are independent of infective dose and route of infection. J. Virol. 77:7696-7701.
39. Sunil-Chandra NP, Efstathiou S, Nash AA. 1992. Murine gammaherpesvirus 68 establishes a latent infection in mouse B lymphocytes in vivo. J. Gen. Virol. 73:3275-3279.
40. Flano E, Husain SM, Sample JT, Woodland DL, Blackman MA. 2000. Latent murine gamma-herpesvirus infection is established in activated B cells, dendritic cells, and macrophages. J. Immunol. 165:1074-1081.
41. Efstathiou S, Preston CM. 2005. Towards an understanding of the molecular basis of herpes simplex virus latency. Virus Res. 111:108-119.
42. Boutell C, Everett RD. 2013. Regulation of alphaherpesvirus infections by the ICP0 family of proteins. J. Gen. Virol. 94:465-481.
43. Cai W, Astor TL, Liptak LM, Cho C, Coen DM, Schaffer PA. 1993. The herpes simplex virus type 1 regulatory protein ICP0 enhances virus replication during acute infection and reactivation from latency. J. Virol. 67: 7501-7512.
44. Leib DA, Coen DM, Bogard CL, Hicks KA, Yager DR, Knipe DM, Tyler KL, Schaffer PA. 1989. Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J. Virol. 63:759-768.
45. Halford WP, Schaffer PA. 2001. ICP0 is required for efficient reactivation of herpes simplex virus type 1 from neuronal latency. J. Virol. 75:3240-3249.
46. Lilley CE, Chaurushiya MS, Boutell C, Landry S, Suh J, Panier S, Everett RD, Stewart GS, Durocher D, Weitzman MD. 2010. A viral E3 ligase targets RNF8 and RNF168 to control histone ubiquitination and DNA damage responses. EMBO J. 29:943-955.
47. Lin R, Noyce RS, Collins SE, Everett RD, Mossman KL. 2004. The herpes simplex virus ICP0 RING finger domain inhibits IRF3-and IRF7-mediated activation of interferon-stimulated genes. J. Virol. 78:1675-1684.
48. Catez F, Picard C, Held K, Gross S, Rousseau A, Theil D, Sawtell N, Labetoulle M, Lomonte P. 2012. HSV-1 genome subnuclear positioning and associations with host-cell PML-NBs and centromeres regulate LAT locus transcription during latency in neurons. PLoS Pathog. 8:e1002852. doi:10.1371/journal.ppat.1002852.
49. Flano E, Kim I-J, Woodland DL, Blackman MA. 2002. Gammaherpesvirus latency is preferentially maintained in splenic germinal center and memory B cells. J. Exp. Med. 196:1363-1372.
50. Willer DO, Speck SH. 2003. Long-term latent murine gammaherpesvirus 68 infection is preferentially found within the surface immunoglobulin D-negative subset of splenic B cells in vivo. J. Virol. 77:8310-8321.